Molecular diagnostics and potential therapeutic options for mycobacterium tuberculosis: Where we stand

Medicine in Omics Pub Date : 2023-06-01 DOI:10.1016/j.meomic.2023.100022

Zafran Khan , Daniya Ualiyeva , Khalid Jamal , Babar Ali , Fayaz Ahmad , Sanjeep Sapkota , Obed Boadi Amissah , Petuel Ndip Ndip Bate

{"title":"Molecular diagnostics and potential therapeutic options for mycobacterium tuberculosis: Where we stand","authors":"Zafran Khan , Daniya Ualiyeva , Khalid Jamal , Babar Ali , Fayaz Ahmad , Sanjeep Sapkota , Obed Boadi Amissah , Petuel Ndip Ndip Bate","doi":"10.1016/j.meomic.2023.100022","DOIUrl":null,"url":null,"abstract":"<div><p><em>Mycobacterium tuberculosis  <!-->strains has intensified this global health issue. Each year the global death tally spikes by 1.6 million, and additional 10.6 million new cases of TB. Researchers are trying to find a treatment, mainly emphasizing the anti-tubercular drugs and/or vaccines that could potentially control the spread of TB to manage the associated health issue. To date, more than 20 anti-tubercular drugs have been developed and used at various stages of TB. The current review aims to discuss/describe useful information about available TB treatments and anti-tubercular resistance. Moreover, we also highlighted diagnostic approaches and current drug reserves for drug-resistant TB (DR-TB).</p></div>","PeriodicalId":100914,"journal":{"name":"Medicine in Omics","volume":"8 ","pages":"Article 100022"},"PeriodicalIF":0.0000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicine in Omics","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590124923000032","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 1

Abstract

Mycobacterium tuberculosis (Mtb) is a causative agent of the infectious disease tuberculosis (TB), which has hampered susceptible populations in modern-day societies for years. Additionally, the emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Mtb strains has intensified this global health issue. Each year the global death tally spikes by 1.6 million, and additional 10.6 million new cases of TB. Researchers are trying to find a treatment, mainly emphasizing the anti-tubercular drugs and/or vaccines that could potentially control the spread of TB to manage the associated health issue. To date, more than 20 anti-tubercular drugs have been developed and used at various stages of TB. The current review aims to discuss/describe useful information about available TB treatments and anti-tubercular resistance. Moreover, we also highlighted diagnostic approaches and current drug reserves for drug-resistant TB (DR-TB).

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

结核分枝杆菌的分子诊断和潜在的治疗选择：我们的立场

结核分枝杆菌（Mtb）是传染病结核病（TB）的病原体，多年来，结核病一直困扰着现代社会的易感人群。此外，耐多药（MDR）和广泛耐药（XDR）结核分枝杆菌菌株的出现加剧了这一全球健康问题。每年，全球死亡人数激增160万，新增1060万结核病病例。研究人员正在努力寻找一种治疗方法，主要强调可能控制结核病传播的抗结核药物和/或疫苗，以解决相关的健康问题。迄今为止，已经开发出20多种抗结核药物，并在结核病的各个阶段使用。目前的综述旨在讨论/描述有关可用结核病治疗和抗结核耐药性的有用信息。此外，我们还强调了耐药结核病的诊断方法和目前的药物储备。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Medicine in Omics

自引率

0.00%

发文量